B Cell Lymphoma
News
Anthracyclines, bendamustine are options for grade 3A follicular lymphoma
A CVP chemotherapy regimen performed poorly compared with anthracycline-based chemotherapy in advanced stage follicular lymphoma.
News
Ibrutinib-MTX-rituximab combo shows promise in CNS lymphoma
The researchers proposed an 840-mg dose of ibrutinib in future studies.
News
Daratumumab disappoints in non-Hodgkin lymphoma trial
The drug, used in multiple myeloma, was safe but ineffective in patients with non-Hodgkin lymphoma.
News
BCL expression intensity key in distinguishing FL lesions
BCL2 expression intensity is the “single most valuable clue” in differentiating primary cutaneous follicular center-cell lymphoma from secondary...
News
Combo appears to overcome aggressive L-NN-MCL
Two case studies highlight the role that P53 gene status plays in prognosis and treatment.
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
News
Imaging, radiotherapy clarified in new PMBCL guidelines
The new good practice paper from the British Society for Haematology also addresses fertility preservation.
Video
Four-drug combo shows durable responses in relapsed/refractory lymphomas
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.
News
Checkpoint inhibitors linked to rare, but serious immune-related side effects
The study breaks down the hematological immune-related side effects of checkpoint inhibitors.
News
Adding umbralisib to ibrutinib produced responses in MCL, CLL
The doublet regimen “is the first successful combination for two drugs targeting B-cell blockade.”